Trulicity Label Update; Canagliflozin Success for CKD; Capsaicin for Weight Loss
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 20, 2018 Category: Cardiology Source Type: news

Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy
Hope that observed renoprotective effects of SGLT2 inhibitors will delay worsening of kidney disease in type 2 diabetes seems to be borne out, as the CREDENCE trial is stopped early.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA ® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 16, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Extends Review Timeline for INVOKANA ® (canagliflozin) Supplemental New Drug Application
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 13, 2018 Category: Pharmaceuticals Source Type: news

New Study Finds No Link Between Canagliflozin and Amputations New Study Finds No Link Between Canagliflozin and Amputations
A large observational study offers reassurance following the doubling of risk seen in CANVAS, although the investigator acknowledges amputations are still'the fly in the ointment'for this drug.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

No Greater Amputation Risk with Canagliflozin in T2D Patients
(MedPage Today) -- Real-world analysis done in over 100,000 canagliflozin users (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 24, 2018 Category: Pediatrics Source Type: news

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA ® (canagliflozin) Compared to Other Diabetes Medications
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 24, 2018 Category: Pharmaceuticals Source Type: news

Real-World Evidence Shows Oral INVOKANA ® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 23, 2018 Category: Pharmaceuticals Source Type: news

New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA ® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 8, 2018 Category: Pharmaceuticals Source Type: news

Hormonal Mechanism Could Explain Canagliflozin's Fracture Risk Hormonal Mechanism Could Explain Canagliflozin's Fracture Risk
If proven, the problem might be managed by measuring 1,25-dihydroxyvitamin D levels in patients and providing calcitriol or vitamin D supplementation for those deficient.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news

Invokana Helps Kidneys Even in Diabetic CKD
(MedPage Today) -- Subanalysis of CANVAS program shows slower progression, fewer events (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2018 Category: Cardiology Source Type: news

INVOKANA ® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 12, 2018 Category: Pharmaceuticals Source Type: news

Canagliflozin May Have Most Benefit in Diabetes With HF: CANVAS Canagliflozin May Have Most Benefit in Diabetes With HF: CANVAS
Exploratory analysis of CANVAS data shows canagliflozin reduced HF hospitalization and cardiovascular death in type 2 diabetes regardless of HF status, and hints at even more benefit for those with HF.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2018 Category: Pharmaceuticals Source Type: news

New Late-Breaking XARELTO ® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 26, 2018 Category: Pharmaceuticals Source Type: news

Canagliflozin Linked to Fewer HF Admissions Than Other Type 2 Diabetes Drugs Canagliflozin Linked to Fewer HF Admissions Than Other Type 2 Diabetes Drugs
Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 20, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting RARITAN, N.J. and NEW ORLEANS, Nov. 3, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen Research & Deve... Biopharmaceuticals, Nephrology Janssen, INVOKANA, canagliflozin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2017 Category: Pharmaceuticals Source Type: news

CANVAS: No Difference in Canagliflozin Effects by Prior CV Status CANVAS: No Difference in Canagliflozin Effects by Prior CV Status
A new analysis of CANVAS finds that canagliflozin reduces CV and renal risks whether the type 2 diabetes patients had prior CVD or not, although a discussant queries benefit in primary prevention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Real-World Analysis Shows INVOKANA ® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 17, 2017 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 14, 2017 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 3, 2017 Category: Pharmaceuticals Source Type: news

CANVAS: Straight Talk Needed on Amputation Risk CANVAS: Straight Talk Needed on Amputation Risk
Can a meta-analysis of two different studies or data from observational studies overcome the clinical concern about the clear-cut amputation risk with canagliflozin seen in the CANVAS trial?Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news

Janssen submits sNDA to FDA for Invokana to reduce risk of MACE
Janssen Research and Development has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA ® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 2, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck
Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen P … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments
Janssen Pharmaceutica has entered an exclusive distribution agreement with Mundipharma Medical Company for Invokana (canagliflozin) and Vokanamet (a fixed-dose combination therapy of canagliflozin and metformin) to treat patients with type 2 diabetes … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 4, 2017 Category: Pharmaceuticals Source Type: news

Some Physicians Switch Patients Off Invokana after FDA Warning
(MedPage Today) -- Doubled risk of amputations appears to be affecting usage (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 2, 2017 Category: Cardiology Source Type: news

Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D
Canagliflozin suppressed the increase in NT-proBNP and high-sensitivity troponin in older patients with type 2 diabetes, which may help shed some light on the beneficial CV effect of SGLT2 inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

FDA Reports Further Support for Canagliflozin-Amputation Link FDA Reports Further Support for Canagliflozin-Amputation Link
The data are still insufficient to change prescribing recommendations, but they do suggest caution in prescribing canagliflozin for people at increased amputation risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

CANVAS Proves CV Safety, Metabolic Value of Canagliflozin CANVAS Proves CV Safety, Metabolic Value of Canagliflozin
British diabetes expert Clifford Bailey offers his take on the CANVAS dataMedscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Some see the newly revealed cardiovascular benefits as rendering canagliflozin essentially"interchangeable" with empagliflozin, while others view the amputation signal as a deal breaker.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Janssen reports positive results from CANVAS programme of canagliflozin
Janssen-Cilag International has reported positive results from the CANVAS programme of INVOKANA (canagliflozin) in combination with standard-of-care to address a combined risk of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and non … (Source: Drug Development Technology)
Source: Drug Development Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news

ADA: Canagliflozin Cuts Heart Risk in T2D (CME/CE)
(MedPage Today) -- But CANVAS program reveals risk of amputation, fracture (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 13, 2017 Category: Consumer Health News Source Type: news

New diabetes pill costs just £1.30 a day
Canagliflozin, a pill taken once a day before breakfast, is designed to lower blood sugar levels and keep weight down. Experts last night said the study heralds a 'new era' in treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - June 13, 2017 Category: Consumer Health News Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 13, 2017 Category: Pharmaceuticals Source Type: news

CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations
Pooled data from two CANVAS trials suggest that cardioprotection is likely a class effect with SGLT2 inhibitors, but it comes at the price of toe amputations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

J & J diabetes drug shows heart benefit in large safety study
(Reuters) - Johnson& Johnson's type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting on Monday. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

J & J Drug Prevents Heart Attacks At Cost Of Amputated Toes
In a blow to J&J, for every three heart attacks, strokes, or cardiovascular deaths prevented by Invokana, there were two amputations, 71% of them of toes or the lower foot, according to the results of the 10,142-patient study. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 12, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:JNJ NYSE:MRK NYSE:LLY Source Type: news

7 medtech stories we missed this week: May 26, 2017
[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufa...
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Patient Monitoring Pharma Pharmaceuticals Research & Development Surgical EarlySense Janssen Pharmaceuticals Life Spine Inc. Masimo MedTech Merck Midmark Procept BioRobotics Shenzhen Lachesis Mhealth Teijin Pharma Thermi Source Type: news

FDA Warns of Amputation Risk Linked to Newer Diabetes Drug
The FDA has called for a new boxed warning to be added to canagliflozin product labels based on a heightened risk for leg and foot amputations associated with use of the drug. (Source: AAFP News)
Source: AAFP News - May 22, 2017 Category: Primary Care Source Type: news

FDA Warning: Diabetes Drug Has Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says (Source: WebMD Health)
Source: WebMD Health - May 17, 2017 Category: Consumer Health News Source Type: news

Diabetes Drug Gets FDA Warning Due to Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says (Source: WebMD Health)
Source: WebMD Health - May 17, 2017 Category: Consumer Health News Source Type: news

Diabetes Drug Gets FDA Warning Due to Amputation Risk
Canagliflozin tied to a doubling of amputations of legs, feet, agency says Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Diabetes Type 2, Limb Loss (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 17, 2017 Category: Consumer Health News Source Type: news

Diabetes Drug Gets FDA Warning Due to Amputation Risk
WEDNESDAY, May 17, 2017 -- The type 2 diabetes prescription drug canagliflozin (brand names Invokana, Invokamet, Invokamet XR) appears to increase the risk of leg and foot amputations, the U.S. Food and Drug Administration now says. The FDA is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 17, 2017 Category: General Medicine Source Type: news

FDA Adds Boxed Warning to Canagliflozin for Increased Amputation Risk (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The FDA is adding new warnings — including a boxed warning — to labels for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 17, 2017 Category: Primary Care Source Type: news

FDA warns of foot, leg amputations with J & J diabetes drug
(Reuters) - Johnson& Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA: Boxed Warning for Canagliflozin on Amputation Risk
(MedPage Today) -- Post-marketing trial data show doubled rates compared to placebo (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 16, 2017 Category: Endocrinology Source Type: news

FDA Adding Boxed Warning to Canagliflozin for Amputation Risk FDA Adding Boxed Warning to Canagliflozin for Amputation Risk
On the basis of new information from two cardiovascular outcomes trials suggesting a doubled amputation risk, the FDA will now require a boxed warning on canagliflozin's label.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Adds Boxed Warning to Canagliflozin for Amputation Risk FDA Adds Boxed Warning to Canagliflozin for Amputation Risk
On the basis of new information from two cardiovascular outcomes trials suggesting a doubled amputation risk, the FDA will now require a boxed warning on canagliflozin's label.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news